ERBB3 and non-small cell lung carcinoma: In similarity to the study reported herein, a recent report found that triple blockade of HER2 and HER3 using two anti-HER2 antibodies and a third, an anti-HER3 mAb, could overcome resistance to trastuzumab [54], and yet another study reported that an anti-HER3 antibody can sensitize refractory NSCLC to erlotinib [55].